# OnCo record paper-reflect-lenvatinib-lancet-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-reflect-lenvatinib-lancet-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-reflect-lenvatinib-lancet-2018" ;
  schema:name "REFLECT: lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma"@en ;
  schema:description "Lenvatinib matched sorafenib for survival in advanced liver cancer while shrinking tumours far more often and delaying progression longer, making it the first new first-line option in ten years."@en ;
  schema:url <https://onco.cc/key-papers/paper-reflect-lenvatinib-lancet-2018/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(18)30207-1>, <https://pubmed.ncbi.nlm.nih.gov/29433850/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(18)30207-1> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Kudo M, Finn RS, Qin S, et al." ;
  onco:cancers <https://onco.cc/cancers/hcc-advanced/> ;
  onco:drugs <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sorafenib/> ;
  onco:trials <https://onco.cc/trials/reflect/> ;
  onco:journals <https://onco.cc/journals/lancet/> .